Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain

Journal of Pain and Symptom Management

Volumn 23, Issue 5, 2002, Pages 355-368

  Palangio, Mark ^a   Northfelt, Donald W ^b   Portenoy, Russell K ^c   Brookoff, Daniel ^d   Doyle Jr , Ralph T ^a   Dornseif, Bruce E ^a   Damask, Michael C ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic malignant pain; Chronic nonmalignant pain; Dose conversion; Extended release; Hydromorphone; Titration

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; GABAPENTIN; HYDROMORPHONE; IMIPRAMINE; NORTRIPTYLINE; OPIATE; PHENYTOIN; SERTRALINE; TRAZODONE; VALPROIC ACID;

ADULT; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HEADACHE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; OUTPATIENT; PAIN ASSESSMENT; SOMNOLENCE; TABLET FORMULATION; TITRIMETRY; VOMITING;

ADULT; ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; NEOPLASMS; PAIN; TITRIMETRY;

EID: 0036242279     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00390-1     Document Type: Article

References (39)

1. Opioid analgesics and antagonists
2. Hydromorphone: Pharmacology and clinical applications in cancer patients
3. Clinical analgesic studies of hydromorphone
4. Subcutaneous infusions for control of cancer symptoms
5. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine
6. Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study
7. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects
8. Effects of controlled-released morphine on quality of life for cancer pain
9. ® and immediate release (IR) hydromorphone (HM) in healthy subjects (abstract)
10. The pharmacokinetics of hydromorphone SR (abstract)
11. Pharmacodynamics of orally administered sustained-release hydromorphone in humans
12. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain
13. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone
14. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain
15. Analgesic efficacy and potency of two oral controlled-release morphine preparations
16. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain
17. Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain
18. Albuterol extended-release products: A comparison of steady-state pharmacokinetics
19. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM
20. Sustained blood pressure control with controlled-release isradipine
21. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties
22. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning
23. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder
24. ® (methylphenidate HCl) formulation
25. More on the conversion of transdermal fentanyl to morphine (letter)
26. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
27. The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine
28. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control?
29. Controversies in the long-term management of analgesic therapy in patients with advanced cancer
30. Efficacy of controlled-release codeine in chronic non-malignant pain: A randomized, placebo-controlled clinical trial
31. Randomized trial of oral morphine for chronic non-cancer pain
32. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: Placebo-controlled trial and long-term evaluation
33. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee
34. Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases
35. Long-term oral opioid therapy in patients with chronic nonmalignant pain
36. The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions
37. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia
38. Placebo-controlled evaluation of the efficacy and safety of controlled release oxycodone in postherpetic neuralgia